These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1093 related articles for article (PubMed ID: 17540196)

  • 21. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
    Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian global registry of acute coronary events (GRACE) experience.
    Banihashemi B; Goodman SG; Yan RT; Welsh RC; Mehta SR; Montalescot G; Kornder JM; Wong GC; Gyenes G; Steg PG; Yan AT;
    Am Heart J; 2009 Dec; 158(6):917-24. PubMed ID: 19958857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bleeding events with antithrombotic therapy in patients with unstable angina or non-ST-segment elevation myocardial infarction; insights from a large clinical practice registry (GRACE).
    Stiles MK; Dabbous OH; Fox KA;
    Heart Lung Circ; 2008 Feb; 17(1):5-8. PubMed ID: 17419100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE).
    Avezum A; Makdisse M; Spencer F; Gore JM; Fox KA; Montalescot G; Eagle KA; White K; Mehta RH; Knobel E; Collet JP;
    Am Heart J; 2005 Jan; 149(1):67-73. PubMed ID: 15660036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved in-hospital outcomes in acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction) despite similar TIMI risk scores.
    Almeda FQ; Hendel RC; Nathan S; Meyer PM; Calvin JE; Klein LW
    J Invasive Cardiol; 2003 Sep; 15(9):502-6. PubMed ID: 12947210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
    Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
    Bolognese L
    Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
    Mehta SR; Steg PG; Granger CB; Bassand JP; Faxon DP; Weitz JI; Afzal R; Rush B; Peters RJ; Natarajan MK; Velianou JL; Goodhart DM; Labinaz M; Tanguay JF; Fox KA; Yusuf S;
    Circulation; 2005 Mar; 111(11):1390-7. PubMed ID: 15781750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of heparins in Non-ST-elevation acute coronary syndromes.
    Gore JM; Spencer FA; Goldberg RJ; Kennelly BM; Fox KA; Allegrone J; Eagle KA; Anderson FA; Steg PG;
    Am J Med; 2007 Jan; 120(1):63-71. PubMed ID: 17208081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
    Lefebvre CW; Hoekstra JW; Bonaca M; Giugliano R
    J Emerg Med; 2009 Feb; 36(2):162-70. PubMed ID: 18353601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome.
    De Servi S; Mariani M; Vandoni P; Dellavalle A; Politi A; Poletti F; Bonizzoni E; Leoncinie M;
    J Cardiovasc Med (Hagerstown); 2006 Mar; 7(3):159-65. PubMed ID: 16645379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of home warfarin use on the treatment and outcomes of patients undergoing percutaneous coronary intervention.
    Aggarwal A; Dai D; Rumsfeld JS; Klein LW; Roe MT
    Am J Cardiol; 2008 May; 101(10):1413-7. PubMed ID: 18471451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality.
    Witkowski A; Maciejewski P; Wasek W; Malek LA; Niewada M; Kaminski B; Drzewiecki J; Kosmider M; Kubica J; Ruzyllo W; Peruga JZ; Dudek D; Opolski G; Dobrzycki S; Gil RJ;
    Eur Heart J; 2009 Jul; 30(14):1736-43. PubMed ID: 19376786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study.
    Huynh T; Piazza N; DiBattiste PM; Snapinn SM; Wan Y; Pharand C; Theroux P
    Int J Cardiol; 2005 Apr; 100(1):73-8. PubMed ID: 15820288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
    Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
    Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-molecular-weight heparins and glycoprotein IIb/IIIa antagonists in acute coronary syndromes.
    Ferguson J
    J Invasive Cardiol; 2004 Mar; 16(3):136-44. PubMed ID: 15152164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treating patients with acute coronary syndromes with aggressive antiplatelet therapy (from the Global Registry of Acute Coronary Events).
    Lim MJ; Eagle KA; Gore JM; Anderson FA; Dabbous OH; Mehta RH; Granger CB; Fox KA; Spencer FA; Goldberg RJ;
    Am J Cardiol; 2005 Oct; 96(7):917-21. PubMed ID: 16188516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of bleeding complications and 3-year survival with low-molecular-weight heparin versus unfractionated heparin for acute myocardial infarction: the FAST-MI registry.
    Puymirat É; Aissaoui N; Silvain J; Bonello L; Cuisset T; Motreff P; Bataille V; Durand E; Cottin Y; Simon T; Danchin N;
    Arch Cardiovasc Dis; 2012; 105(6-7):347-54. PubMed ID: 22800719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.
    Alexander KP; Chen AY; Roe MT; Newby LK; Gibson CM; Allen-LaPointe NM; Pollack C; Gibler WB; Ohman EM; Peterson ED;
    JAMA; 2005 Dec; 294(24):3108-16. PubMed ID: 16380591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.
    Chew DP; Huang Z; Pieper KS; White H; Mahaffey KW; Ferguson JJ; Califf RM; Aylward PG
    Am Heart J; 2008 Feb; 155(2):239-44. PubMed ID: 18215592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.